ICD-10-CM Code T45.1X5
Adverse effect of antineoplastic and immunosuppressive drugs
7th Character Required
Non-Billable CodeNon-Billable means the code is not sufficient justification for admission to an acute care hospital when used a principal diagnosis. Use a child code to capture more detail.
| ICD-10 from 2011 - 2016
7th Character RequiredCode requires 7th Character Extension identifier. This 7th Character usually captures Episode of Care information, such as "Initial Encounter," "Subsquent Encounter," or "Sequela."
ICD Code T45.1X5 is a non-billable code. To code a diagnosis of this type, you must use specify a 7th character that describes the diagnosis 'adverse effect of antineoplastic and immunosuppressive drugs' in more detail. The 7th characters that can be added, and the resulting billable codes, are as follows:
|7th Digit||Billable Code||7th Digit Specifies|
What is 7th Character Extension?For codes less than 6 characters that require a 7th character a placeholder 'X' should be assigned for all characters less than 6. The 7th character must always be the 7th position of a code. E.g. The ICD-10-CM code T67.4 (Heat exhaustion due to salt depletion) requires an Episode of Care identifier. T67.4XXA Initial Encounter or T67.4XXD Subsequent Encounter. More Info
Related Concepts SNOMET-CT
- Chemotherapy sickness (disorder)
- Neurotoxicity due to L-asparaginase (disorder)
- Mucositis following chemotherapy (disorder)
- Stomatitis due to cytotoxic therapy (disorder)
- Acral erythema due to cytotoxic therapy (disorder)
- Fatigue due to chemotherapy or radiation therapy (disorder)
Coding Advice SNOMET-CT
- Episode of care information needed
- Consider additional code to identify specific condition or disease
ICD-10-CM Drugs Index References for 'T45.1X5 - Adverse effect of antineoplastic and immunosuppressive drugs'
The ICD-10-CM Drugs Index links the below-listed medical terms to the ICD code T45.1X5. Click on any term below to browse the drugs index.
Parent Code: T45.1 - Poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drugs